Neratinib (an irreversible inhibitor of HER1, HER2, and HER4) showed an overall survival rate of 12%, with a decrease in gallbladder tumor size or extrahepatic location in patients with advanced BC and HER2 mutation [53]. This evidence concerns the gene ERBB2 and breast cancer.